A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example

Open Access

Peer-reviewed

Research Article

Tjeerd-Pieter van Staa ,

* E-mail: Tjeerd.vanstaa@GPRD.com

Affiliations General Practice Research Database, London, United Kingdom, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
⨯
Hubert G. Leufkens,

Affiliation Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
⨯
Bill Zhang,

Affiliation General Practice Research Database, London, United Kingdom
⨯
Liam Smeeth

Affiliation London School of Hygiene & Tropical Medicine, London, United Kingdom
⨯

Reader Comments (0)

NSAIDs
Is the Subject Area "NSAIDs" applicable to this article?

Thanks for your feedback.
Cost-effectiveness analysis
Is the Subject Area "Cost-effectiveness analysis" applicable to this article?

Thanks for your feedback.
Randomized controlled trials
Is the Subject Area "Randomized controlled trials" applicable to this article?

Thanks for your feedback.
Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.
Technology assessment
Is the Subject Area "Technology assessment" applicable to this article?

Thanks for your feedback.
Cardiovascular disease risk
Is the Subject Area "Cardiovascular disease risk" applicable to this article?

Thanks for your feedback.
Epidemiology
Is the Subject Area "Epidemiology" applicable to this article?

Thanks for your feedback.